WO2004026334A1 - Antimicrobial composition and method for use - Google Patents
Antimicrobial composition and method for use Download PDFInfo
- Publication number
- WO2004026334A1 WO2004026334A1 PCT/CA2003/001359 CA0301359W WO2004026334A1 WO 2004026334 A1 WO2004026334 A1 WO 2004026334A1 CA 0301359 W CA0301359 W CA 0301359W WO 2004026334 A1 WO2004026334 A1 WO 2004026334A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antimicrobial composition
- antimicrobial
- livestock
- substance
- sequestering agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/189—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/195—Antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Definitions
- the present invention relates to a composition and method for suppressing the growth of microorganisms in the gut of livestock, and more particularly, to an antimicrobial composition that can be administered to livestock as an additive to water or feed to suppress the growth of pathogenic microorganisms in the gut.
- One such bacterium that causes intestinal disease is Clostridium perfringens, which causes necrotic enteritis (“NE”) in poultry and Clostridium perfringens enteritis (“CPE”) in swine.
- NE necrotic enteritis
- CPE Clostridium perfringens enteritis
- Escherichia coli another common enteric pathogen, causes disease in many types of animals, such as diarrheal disease in piglets. Every year NE, CPE and diarrheal diseases impose significant financial losses to the bird and pig farming industries.
- various serotypes of Salmonella cause diseases in animals which can be transmitted to humans through the consumption of animal food products.
- NE was first described as a domestic avian disease in 1961. Clostridium perfringens is found naturally occurring in the avian gut. Under favorable conditions, however, Clostridium perfringens can multiply quickly and release toxins, which cause gross lesions consisting of large areas of necrosis in the lining of the lower small intestine. In some cases the bacteria can also affect the caeca and the liver. Favorable conditions leading to the proliferation of Clostridium perfringens can be induced by intestinal stresses caused by dietary risk factors and other factors such as coccidiosis etc., acting as predisposing factors for the disease.
- NE tends to occur as an outbreak, principally affecting birds between the age range of two to five weeks and is characterized by an acute course of loss of appetite, depression, ruffled feathers, diarrhea and decreased weight gain which may also be followed by sudden death.
- the mortality rate in untreated flocks can reach 10% or more.
- Clostridium perfringens type A and type C cause diarrhea, decreased weight gain and sometimes death in acute forms.
- Bacterial diarrhea otherwise known as diarrheal disease has generally become an economically important disease in the livestock industry and more particularly in swine, as a result of increasing intensification of farrowing management - a trend towards large herds and early weaning.
- the diarrheal disease caused by enterotoxigenic Eschericfiia coli is the most common enteric disease encountered in neonatal pigs.
- Escherichia coli colonizes in the gut by adhering to the epithelium of the small intestine. Once the E. coli colonizes, the bacteria then produce toxins that cause gastrointestinal disorders. The process of infestation can occur in both neonatal and post-weaning piglets.
- the post-weaning infection of Escherichia coli is a major cause of economic loss in the swine industry due to reduced growth rates and increased mortality rates.
- a variety of antibiotics such as virginiamycin and bacitracin have been used to control and prevent Clostridium perfringens and other related diseases. These antibiotics are administered to various avian and swine populations by adding it to their feed. The continued development of resistance to and against feed grade antibiotics, however, has caused a setback in the prevention and control of the above-mentioned diseases. Further, in July 1999, the European community banned the use of feed-grade antibiotics, including virginiamycin and bacitracin. A similar action may soon be undertaken in the rest of the world due to the increasing public awareness of the negative impacts of antibiotic use and its affect on the environment and human health.
- the antimicrobial composition includes lysozyme in combination with an antimicrobial substance and a sequestering agent to reduce the growth of and diseases or epidemiological significant effects caused by Clostridium perfinigens, E. coli and Salmonella, and to address at least some of the problems identified above.
- the antimicrobial composition and method according to embodiments of the invention suppress various types of bacteria that may be present in vivo in the avian and swine guts which may affect the animals' health and can lead to complications such as decreased weight gain and death. More particularly, the antimicrobial composition and method relate to a water or feed additive that can be administered to livestock to inhibit the growth of Clostridium perfringens, which causes NE in poultry and CPE in swine. The use of such a water or feed additive may also inhibit the growth of E. coli which causes diarrheal disease in swine and may also inhibit the growth of Salmonella Typhimurium and Salmonella Mbandaka, including other enteric pathogens present in the avian and swine guts.
- a method for suppressing the growth of enteric pathogens in the gut of livestock and the incidence of diseases related thereto including administering an antimicrobial composition to the livestock, the antimicrobial composition including:
- the ratio of the cell wall lysing substance or its salt, the antimicrobial substance and the sequestering agent is 2:5:3 by weight.
- enteric pathogens targeted include members of the following families of bacteria: Clostridium perfringens, Escherichia coli, Salmonella Typhimurium and Salmonella Mbandaka.
- the cell wall lysing substance or its salt may be lysozyme.
- the antimicrobial substance may be dried egg powder and /or albumen.
- the sequestering agent may be an organic acid and /or a metal-chelator and may be selected from disodium ethylenediaminetetraacetate (EDTA), citric acid or chitosan.
- EDTA disodium ethylenediaminetetraacetate
- citric acid citric acid
- chitosan disodium ethylenediaminetetraacetate
- composition further comprises a lantibiotic which may be nisin.
- the antimicrobial composition is in powdered or aqueous solution form.
- the antimicrobial composition is administered as a feed additive.
- the administration of the antimicrobial composition is to suppress the incidence of or treat necrotic enteritis, Clostridium perfringens enteritis and diarrheal disease.
- the dried egg powder may suppress the growth of additional microbes such as molds and viruses in the livestock gut. Further, the dried egg powder may also suppress additional enzymes such as proteases and lipases in the livestock gut.
- the antimicrobial composition can be administered in aqueous form by mixing the antimicrobial composition with drinking water for the livestock where the antimicrobial composition may have a final concentration of approximately 100 to 200 parts per million.
- the antimicrobial composition can be administered as a food additive where the antimicrobial composition may have a final concentration of approximately 100 to 200 parts per million.
- a method for suppressing the growth of enteric pathogens in the gut of livestock and the incidence of diseases related thereto including administering an antimicrobial composition to the livestock, the antimicrobial composition comprising: (a) a cell wall lysing substance or its salt;
- the ratio of the cell wall lysing substance or its salt, the antimicrobial substance, the sequestering agent and the lantibiotic are approximately 50:150:50:20 by weight.
- an antimicrobial composition for suppressing the growth of enteric pathogens in the gut of livestock and the incidence of diseases related thereto comprising:
- enteric bacterial pathogens targeted include members of the following families of bacteria: Clostridium perfringens, Escherichia coli, Salmonella Typhimurium and Salmonella Mbandaka.
- the cell wall lysing substance or its salt may be lysozyme.
- the antimicrobial substance may be dried egg powder and /or albumin.
- the sequestering agent may be an organic acid and /or metal-chelator and may be selected from disodium ethylenediamine tetraacetate (EDTA), citric acid or chitosan.
- EDTA disodium ethylenediamine tetraacetate
- the lantibiotic may be nisin.
- the antimicrobial composition may be in powdered or aqueous solution form.
- the antimicrobial composition may be a feed additive.
- Fig. 1 illustrates the minimal inhibitory concentration (MIC) of lysozyme against Cl. perfringens
- Fig. 2 illustrates the MIC of a blend containing lysozyme, albumen and citric acid at a ratio of 50:100:50 against Cl. perfringens;
- Fig. 3 illustrates the inhibition of Cl. perfringens by lysozyme, disodium EDTA and dried egg powder at a ratio of 2:3:5 (Inovapure ® Plus 532 from Canadian Inovatech Inc., Abbotsford, B.C., Canada) at concentrations of 100 and 200 ppm;
- FIG. 4 illustrates the MIC of Inovapure ® Plus 532 against E. coli
- FIG. 5 illustrates the MIC of Inovapure ® Plus 532 against Salmonella Typhimurium
- Fig. 6 illustrates the MIC of Inovapure ® Plus 532 against Salmonella Mbandaka
- FIG. 7 illustrates the fractional inhibitory concentration (FIC) of lysozyme and nisin against Cl. perfringens.
- Fig. 8 illustrates the effect of lysozyme, nisin, citric acid and albumen against Cl. perfringens.
- lysozyme also know as EC 3.2.1.17 or muramidase
- lysozyme naturally occurs in several mammalian secretions such as milk, saliva and tears.
- lysozyme is extracted from hen egg whites due to its natural abundance, including approximately 3% of the protein.
- Lysozyme is a 14.6 kDa single peptide protein that can lyse bacterial cells by cleaving the ⁇ (1-4) glycosidic linkage between ⁇ /-acetylmuramic acid and N- acetylglucosamine in the peptidoglycan layer. Lysozyme has an extremely high isoelectric point (>10) and consequently is highly cationic at a neutral or acid pH. In solution, lysozyme is relatively stable at a low pH. It is also active over the temperature range of 1°C to near boiling, approximately 100°C.
- Lysozyme is effective against certain Gram-positive bacteria including the Clostridium species.
- Clostridium species include the Clostridium species.
- lysozyme has been used in the cheese industry as a bio-protectant for more than 20 years to prevent butyric spoilage, which causes the late blowing of semi-hard cheeses, by Clostridium tyrobutyricum.
- an antimicrobial composition containing lysozyme may also act more particularly as an antibacterial to control and prevent enteric pathogenic bacterial related diseases in livestock by administering the antimicrobial composition to livestock through their feed.
- lysozyme is effective in inhibiting the pathogenic bacteria Clostridium perfringens.
- Figure 1 illustrates the data obtained from the minimal inhibitory concentration ("MIC") plates for lysozyme against Clostridium perfringens.
- lysozyme shows efficacy for inhibiting Clostridium perfringens at a dose of between 100 and 200 ppm. Lysozyme may be added to animal feed and more particularly, bird and swine feed, at this concentration in order to control and prevent the enteric pathogenic effects of Clostridium prefringens, along with other bacterial growth.
- an antimicrobial composition containing a cell wall lysing substance, such as lysozyme, an antimicrobial substance, preferably dried egg powder/albumin and a sequestering agent or metal-chelating agent are administered to livestock to reduce the incidence of the above mentioned bacterial related diseases.
- a cell wall lysing substance such as lysozyme
- an antimicrobial substance preferably dried egg powder/albumin
- a sequestering agent or metal-chelating agent are administered to livestock to reduce the incidence of the above mentioned bacterial related diseases.
- a sequestering/metal-chelating agent such as disodium ethyiene diamine tetraacetic acid (disodium EDTA), citric acid or chitosan
- Figure 2 illustrates the MIC plates of Clostridium perfringens inoculated with a 100 times dilution of an overnight culture.
- the mixture (Blend 1) contains lysozyme, albumen and citric acid in a ratio of 1 :3:1.
- Figure 2 illustrates that there is an efficacy for inhibiting Clostridium perfringens at approximately 50ppm when using the above-described Blend 1 on MIC plates. It should be noted that, although the relative amount of lysozyme used in the present pilot study decreased compared to the concentration used in the pilot study of Figure 1, the efficacy of the composition increased. It is also important to note that lysozyme represents only a fraction of Blend 1 used in the presently described pilot study (50 ppm) that led to the generation of the data illustrated in Figure 2.
- An advantage of this embodiment of the invention is the relative low costs of both albumen and citric acid as compared to lysozyme. Given current prices, Blend 1 would cost approximately USD$3/MTF at 50ppm in order to be effective in controlling Clostridium perfringens.
- the sequestering agent metal- chelating agent i.e. citric acid
- the sequestering agent metal- chelating agent may also help to prevent the growth of Gram negative pathogens such as Escherichia colian ⁇ Salmonella.
- Gram negative pathogens such as Escherichia colian ⁇ Salmonella.
- Blend 1 it was found that there was an increase in antimicrobial activity against Gram negative pathogens. It has been suggested that the reason for this is that the sequestering/metal-chelating agent works as an anti-oxidant and is synergistic with lysozyme in these situations.
- an antimicrobial composition containing lysozyme, disodium EDTA and dried egg powder may be added to the feed of livestock and more particularly, poultry and /or swine in order to control and suppress bacteria and bacterial related diseases.
- a blend Inovapure ® PlusTM 532 from Canadian Inovatech Inc., Abbotsford, B.C., Canada is synergistic and successful at controlling Clostridium perfringens. The results from the pilot study are illustrated in Figure 3.
- Clostridium perfringens was inoculated at 10 5 CFU/ml in LB medium supplemented with 0.15% NaCI. Both 100 ppm and 200 ppm of the Inovapure ® Plus 532 successfully inhibited the growth of the Clostridium perfringens. Furthermore a dose response was evidenced by the fact that the 200 ppm solution was more successful.
- disodium EDTA as the metal-chelator is that it is an approved ingredient for use in animal feed in both Canada and the United States.
- EDTA itself has antimicrobial properties because it limits the availability of cations in a solution.
- EDTA complexes with the cations that act as salt bridges between membrane macromolecules, such as lipopolysaccharides causing the bacterial cell membranes to become unstable and lyse.
- lysozyme and EDTA have been observed on other types of microorganisms, such as, Gram-positive bacteria, more particularly, Staphylococcus aureus and various Gram negative bacteria. Lysozyme and EDTA have also been observed to be effective on certain types of fungi.
- Figures 4, 5 and 6 illustrate the MIC of Inovapure ® Plus 532 against clinical isolates of Salmonella Typhimurium, Salmonella Mbandaka, and Escherichia coli.
- Figure 4 illustrates that the efficacy for inhibiting Escherichia coli with Inovapure ® Plus 532 was approximately 1250 ppm while the cultures of Salmonella were both inhibited at approximately 2500 ppm.
- a further benefit obtained from the use of lysozyme and EDTA is that it is known that both lysozyme and EDTA have a direct inhibitory effect on the enzymatic activity of phospholipase C (or the alpha toxin produced by Clostridium perfringens) which causes intestinal lesions, a further benefit of the embodiment of the invention.
- the synergies of the dried egg proteins also serve to inhibit the toxins that are produced by Clostridium perfringens.
- immunoglobulin Y IgY
- derived from dried egg proteins see, for example, Erhard, M.H., Gobel, E., Lewan, B., Losch, U., Stangassinger, M., 1997.
- a composition further containing a lantibiotic may be formed to also suppress gram-positive bacterial growth and related diseases in livestock and more particularly, in avian and swine populations.
- a lantibiotic such as nisin
- Figure 7 illustrates experimental data relating to the synergies between nisin and lysozyme obtained during this pilot study.
- Fractional inhibitory concentration (“FIC") plates of Clostridium perfringens were inoculated with a 100 times dilution of an overnight culture. It should be noted that lysozyme was effective alone in this pilot study at approximately 120ppm. By increasing the amount of nisin in the pilot study to 3 ppm, only 8 ppm of lysozyme was required to achieve a bactericidal effect on Clostridium perfringens.
- an antimicrobial composition containing lysozyme, powdered egg and/or albumen, a sequestering/metal- chelating agent and a lantibiotic can be administered to livestock to suppress bacterial growth and bacterial related diseases in livestock and more particularly in avian and swine populations.
- the composition is added to the water or feed of an avian and /or swine population to prevent enteric bacterial related diseases.
- composition containing a lantibiotic, such as nisin, lysozyme, albumen and a sequestering/metal-chelating agent, such as citric acid has a high efficacy for inhibiting Clostridium perfringens due to the synergies between lysozyme, nisin, albumen and citric acid.
- Figure 8 illustrates experimental data relating to the synergies between nisin, lysozyme, citric acid and albumen as determined from the pilot study.
- Figure 8 shows MIC plates of Clostridium perfringens inoculated with a 100 times dilution of an overnight culture.
- Blend 2 and Blend 3 contained lysozyme, nisin, citric acid and albumen in the ratios of 33:17:50:150 and 50:20:50:150 (Inovapure ® Plus), respectively.
- Figure 8 shows that the effective dosage of the combination of Blend 3, against Clostridium perfringens, is approximately 20 ppm.
- the effective dosage decreased from approximately 50ppm (as seen in Blend 1 Figure 2) to 20 ⁇ pm.
- the amount of lysozyme in the mixture represents only a portion of the total antimicrobial composition.
- An additional advantage of this embodiment of the invention is that a blend of lysozyme, nisin, citric acid and albumen for maintaining efficacy by inhibiting Clostridium perfringens at 20ppm currently costs approximately less than $1USD/MTF.
- necropsy The carcasses of the birds that died during the trial were taken for lesion scoring, by way of necropsy by an investigator. The purpose of the necropsy was to determine the most probable cause of death or morbidity. NE was diagnosed as the cause of mortality if intestinal lesions were noted.
- the feed that was administered to the birds during the study was a non-medicated starter and grower basal feed.
- the diets were set forth as starter (Day 0 to 18) and grower (Day 18 to 27). These timelines were considered to represent local industry diets. In addition, the feed consumption of the birds was monitored.
- a further floor pen study was conducted in which an antimicrobial composition was administered including Inovapure ® Plus 532.
- the Applicant undertook the pilot study in order to evaluate the effect of dietary Inovapure Plus 532 at 100 and 200 ppm on the performance of broiler chickens grown in a floor pen environment, challenged with Clostridium perfringens t p A.
- the antimicrobial composition as described above, was fed to the birds continuously for the entire grow-out.
- the antimicrobial composition was mixed with a complete diet at an inclusion rate of 0, 100, or 200 ppm.
- the antimicrobial composition was made into an intermediate premix by adding the entire amount required for each tonne with 5 Kg of a major ingredient, such as wheat, and thoroughly mixing by hand. The intermediate premix was then added to the entire mix and blended.
- a coccidial challenge was administered to the chicks to stimulate Clostridium proliferation in the intestine of the birds.
- the method of administration of antimicrobial composition to livestock, including both avian and swine populations is preferably via the oral route through drinking water or feed.
- the composition may be produced in a powder form and then dissolved in the drinking water to yield a final concentration of approximately 100 to 200 ppm.
- the active ingredients should be selected to be readily soluble.
- the antimicrobial composition is preferably added to a subset of the basal diet of an animal to form a premix at approximately 1 to 2% concentration.
- the pre-mix can then be mixed into the final feed at approximately 100 to 200 ppm.
- the blend should be used in starter, grower and finisher feeds.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0314118A BRPI0314118B1 (en) | 2002-09-18 | 2003-09-18 | antimicrobial composition as an agent for suppressing the development of enteric pathogens in the intestine of farmed animals and / or for the prevention and treatment of gastrointestinal infections in farmed animals |
DE60317799T DE60317799T2 (en) | 2002-09-18 | 2003-09-18 | ANTIMICROBIAL COMPOSITION AND METHOD OF USE |
US10/528,210 US20050266050A1 (en) | 2002-09-18 | 2003-09-18 | Antimicrobial composition and method for use |
EP03797125A EP1539224B1 (en) | 2002-09-18 | 2003-09-18 | Antimicrobial composition and method for use |
JP2004536716A JP4664678B2 (en) | 2002-09-18 | 2003-09-18 | Antibacterial compositions and methods for use |
AU2003266058A AU2003266058A1 (en) | 2002-09-18 | 2003-09-18 | Antimicrobial composition and method for use |
DK03797125T DK1539224T3 (en) | 2002-09-18 | 2003-09-18 | Antimicrobial preparation and method of use |
CA2498143A CA2498143C (en) | 2002-09-18 | 2003-09-18 | Antimicrobial composition and method for use |
US12/752,596 US20110014178A1 (en) | 2002-09-18 | 2010-04-01 | Antimicrobial Composition and Method for Use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002404356A CA2404356A1 (en) | 2002-09-18 | 2002-09-18 | Gram-positive antibacterial composition and method for use |
CA2,404,356 | 2002-09-18 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/752,596 Division US20110014178A1 (en) | 2002-09-18 | 2010-04-01 | Antimicrobial Composition and Method for Use |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004026334A1 true WO2004026334A1 (en) | 2004-04-01 |
Family
ID=32000084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2003/001359 WO2004026334A1 (en) | 2002-09-18 | 2003-09-18 | Antimicrobial composition and method for use |
Country Status (10)
Country | Link |
---|---|
US (2) | US20050266050A1 (en) |
EP (2) | EP1539224B1 (en) |
JP (1) | JP4664678B2 (en) |
AU (1) | AU2003266058A1 (en) |
BR (1) | BRPI0314118B1 (en) |
CA (2) | CA2404356A1 (en) |
DE (1) | DE60317799T2 (en) |
DK (1) | DK1539224T3 (en) |
ES (1) | ES2298614T3 (en) |
WO (1) | WO2004026334A1 (en) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007113691A3 (en) * | 2006-04-06 | 2007-12-27 | Sanofi Aventis Spa | Peptide compound with biological activity, its preparation and its application |
EP2124575A2 (en) * | 2006-12-26 | 2009-12-02 | Sterilex Technologies, LLC | Antimicrobial compositions |
WO2011104339A1 (en) | 2010-02-25 | 2011-09-01 | Novozymes A/S | Variants of a lysozyme and polynucleotides encoding same |
WO2012035103A1 (en) | 2010-09-16 | 2012-03-22 | Novozymes A/S | Lysozymes |
WO2013076253A1 (en) | 2011-11-25 | 2013-05-30 | Novozymes A/S | Polypeptides having lysozyme activity and polynucleotides encoding same |
WO2013110627A1 (en) | 2012-01-23 | 2013-08-01 | Morphosys Ag | Use of lysozyme as a tag |
WO2017001703A1 (en) | 2015-07-02 | 2017-01-05 | Novozymes A/S | Methods of improving animal performance |
WO2017140807A1 (en) | 2016-02-16 | 2017-08-24 | Monaghan Mushrooms Group | Fungal polypeptides having lysozyme activity |
WO2018127532A1 (en) | 2017-01-04 | 2018-07-12 | Novozymes A/S | Microbial lysozyme for use in the treatment of irritable bowel syndrome or inflammatory bowel disease |
WO2019043191A1 (en) | 2017-09-01 | 2019-03-07 | Novozymes A/S | Animal feed additives comprising a polypeptide having protease activity and uses thereof |
WO2019043189A1 (en) | 2017-09-01 | 2019-03-07 | Novozymes A/S | Animal feed additives comprising polypeptide having protease activity and uses thereof |
WO2019170682A1 (en) | 2018-03-05 | 2019-09-12 | Novozymes A/S | Ruminant feed composition comprising a muramidase |
WO2019177171A1 (en) | 2018-03-16 | 2019-09-19 | 味の素株式会社 | Animal feed additive and animal feed |
WO2020043836A1 (en) | 2018-08-31 | 2020-03-05 | Novozymes A/S | Polypeptides having protease activity and polynucleotides encoding same |
WO2020053274A1 (en) | 2018-09-11 | 2020-03-19 | Dsm Ip Assets B.V. | Animal feed composition and use thereof |
WO2020053271A1 (en) | 2018-09-11 | 2020-03-19 | Dsm Ip Assets B.V. | Animal feed composition and use thereof |
WO2020053275A2 (en) | 2018-09-11 | 2020-03-19 | Dsm Ip Assets B.V. | Animal feed composition and use thereof |
WO2020053273A1 (en) | 2018-09-11 | 2020-03-19 | Dsm Ip Assets B.V. | Animal feed composition and use thereof |
WO2020053276A1 (en) | 2018-09-11 | 2020-03-19 | Dsm Ip Assets B.V. | Animal feed composition and use thereof |
WO2020058223A1 (en) | 2018-09-17 | 2020-03-26 | Dsm Ip Assets B.V. | Animal feed composition and use thereof |
WO2020182602A1 (en) | 2019-03-11 | 2020-09-17 | Novozymes A/S | Fibrous maize-based animal feed with gh30 glucuronoxylan hydrolase |
WO2022194728A1 (en) | 2021-03-16 | 2022-09-22 | Dsm Ip Assets B.V. | Animal feed composition and use thereof |
US11859170B2 (en) | 2017-05-12 | 2024-01-02 | Novozymes A/S | Polypeptides having lysozyme activity, polynucleotides encoding same and uses and compositions thereof |
JP7484885B2 (en) | 2018-09-11 | 2024-05-16 | ディーエスエム アイピー アセッツ ビー.ブイ. | Animal feed composition and use thereof |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI276682B (en) * | 2001-11-16 | 2007-03-21 | Mitsubishi Chem Corp | Substrate surface cleaning liquid mediums and cleaning method |
US7348301B2 (en) * | 2006-02-16 | 2008-03-25 | Buckman Laboratories International, Inc. | Lysozyme-based method and composition to control the growth of microorganisms in aqueous systems |
DK2176284T3 (en) | 2007-07-20 | 2013-10-14 | Univ Minnesota | LANTIBIOTICS AND APPLICATIONS THEREOF |
ITMI20111555A1 (en) * | 2011-08-29 | 2013-03-01 | Cevolani Daniele S R L | FEED AND COMPOSITIONS FOR VETERINARY AND / OR LIVESTOCK USE |
RU2504386C1 (en) * | 2012-12-18 | 2014-01-20 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" | Preparation for prevention of diarrhoea in newborn calves |
EP3651739A4 (en) * | 2017-07-10 | 2021-04-07 | Contrafect Corporation | Blood component potentiation of lytic protein anti-bacterial activity and methods and uses thereof |
WO2019018368A1 (en) * | 2017-07-17 | 2019-01-24 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Antibacterial methods and related kits |
CN110692850A (en) * | 2019-10-09 | 2020-01-17 | 北京首朗生物科技有限公司 | Application of clostridium ethanolate protein in poultry feed |
CN116847872A (en) * | 2021-02-16 | 2023-10-03 | 帝斯曼知识产权资产管理有限公司 | Method for reducing pathogenic E.coli by intervention with a selective feed additive comprising an enzyme such as a muramidase |
CN115105490B (en) * | 2022-06-16 | 2024-01-30 | 青岛农业大学 | Plant essential oil composition for inhibiting clostridium perfringens and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62145025A (en) * | 1985-12-18 | 1987-06-29 | Nippon Kayaku Co Ltd | Antiviral agent |
EP0466244A1 (en) * | 1990-07-13 | 1992-01-15 | Unilever N.V. | Compositions having antibacterial properties and use of such compositions in suppressing growth of microorganisms, eg. Listeria bacteria |
EP0955061A1 (en) * | 1998-03-20 | 1999-11-10 | Medipharm CZ, s.r.o. | Oral product for the prevention and therapy of porcine gastroenteric infections |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4073884A (en) * | 1976-09-27 | 1978-02-14 | W. R. Grace & Co. | Promotion of feed efficiency |
US4968493A (en) * | 1986-06-30 | 1990-11-06 | American Cyanamid Company | Method for controlling chronic respiratory disease, fowl cholera and necrotic enteritis in avian species |
US5597564A (en) * | 1986-08-28 | 1997-01-28 | Enzacor Properties Limited | Method of administering a microgranular preparation to the intestinal region of animals |
US5356625A (en) * | 1986-08-28 | 1994-10-18 | Enzacor Properties Limited | Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals |
US5314962A (en) * | 1987-04-07 | 1994-05-24 | Mitsubishi Petrochemical Company Limited | ABA type block copolymers |
US5314692A (en) * | 1987-08-24 | 1994-05-24 | Cultor Ltd. | Enzyme premix for feed and method |
US5135910A (en) * | 1988-06-22 | 1992-08-04 | The Public Health Research Institute Of The City Of New York | Nisin compositions for use as enhanced, broad range bactericides |
DE3841152A1 (en) * | 1988-12-07 | 1990-06-13 | Hoechst Ag | USE OF BACTERIA-LYING ENZYME PRODUCT AS AN ADDITIVE TO IMPROVE THE FEED RECYCLING IN ANIMAL PRODUCTION |
US5458876A (en) * | 1988-12-21 | 1995-10-17 | Haarman & Reimer Corp. | Control of microbial growth with lantibiotic/lysozyme formulations |
US5573797A (en) * | 1989-02-21 | 1996-11-12 | Viskase Corporation | Film and method for surface treatment of foodstuffs with antimicrobial compositions |
US5573800A (en) * | 1989-02-21 | 1996-11-12 | Viskase Corporation | Antimicrobial composition for surface treatment of foodstuffs |
US5573801A (en) * | 1989-02-21 | 1996-11-12 | Viskase Corporation | Surface treatment of foodstuffs with antimicrobial compositions |
DK0389795T3 (en) * | 1989-02-25 | 1993-08-02 | Morinaga Milk Industry Co Ltd | Bioactive agents |
DE69014030T3 (en) * | 1989-09-05 | 1999-06-24 | Ajinomoto Kk | Means for the prevention and treatment of diarrhea. |
US5041236A (en) * | 1989-10-27 | 1991-08-20 | The Procter & Gamble Company | Antimicrobial methods and compositions employing certain lysozymes and endoglycosidases |
US5601823A (en) * | 1989-10-31 | 1997-02-11 | Ophidian Pharmaceuticals, Inc. | Avian antitoxins to clostridium difficle toxin A |
US5736139A (en) * | 1989-10-31 | 1998-04-07 | Ochidian Pharmaceuticals, Inc. | Treatment of Clostridium difficile induced disease |
NZ236795A (en) * | 1990-03-13 | 1992-05-26 | Microlife Technics | Bacteriocin from lactococcus with molecular weight about 6000 and devices and foods containing it |
US5015487A (en) * | 1990-04-23 | 1991-05-14 | Haarmann & Reimer Corp. | Use of lanthionines for control of post-processing contamination in processed meat |
US5043176A (en) * | 1990-06-13 | 1991-08-27 | Haarmann & Reimer Corp. | Synergistic antimicrobial compositions |
US5902579A (en) * | 1991-08-05 | 1999-05-11 | Bio-Technical Resources | Natamycin-containing streptomyces biomass and its use in animal feed |
US5342612A (en) * | 1991-12-20 | 1994-08-30 | American Cyanamid Company | Compositions for the treatment of mammalian diseases |
JPH06145066A (en) * | 1992-02-15 | 1994-05-24 | Imuno Japan:Kk | Medical composition for enhancement of effect of chemotherapeutic agent and for prevention and improvement of infectious disease |
DK0642581T3 (en) * | 1992-05-20 | 2003-02-17 | Secr Defence | Clostridium perfringens vaccines |
FI102807B1 (en) * | 1994-08-25 | 1999-02-26 | Valio Oy | Use of Lactobacillus rhamnosus in the food industry to inhibit clostridia |
IES70514B2 (en) * | 1995-04-12 | 1996-12-11 | Teagasc Agric Food Dev Authori | Bacteriocins |
CN1216446A (en) * | 1996-04-23 | 1999-05-12 | 诺沃挪第克公司 | Animal feed additives |
US5741489A (en) * | 1996-05-24 | 1998-04-21 | Anitox Corporation | Passively administered antibody that enhances feed conversion efficiency |
DE69739845D1 (en) * | 1996-09-05 | 2010-05-27 | Univ Alberta | NOVEL BACTERIOCINE, TRANSPORT AND VECTOR SYSTEM AND METHOD FOR THEIR USE |
US5932469A (en) * | 1997-06-10 | 1999-08-03 | University Of Florida | Antimicrobial polypeptide, nucleic acid, and methods of use |
FR2765078B1 (en) * | 1997-06-27 | 1999-09-17 | Guyomarc H Nutrition Animale | METHOD FOR IMPROVING THE EFFECTIVENESS OF A PROBIOTIC, PREPARATION OF FOOD ADDITIVES AND ANIMAL FEED CONTAINING IT |
SE511025C2 (en) * | 1997-10-03 | 1999-07-26 | Probi Ab | Horse feed product comprising Lactobacillus plantarum JI: 1 and Lactobacillus plantarum JI: 1 and use thereof |
US20020037260A1 (en) * | 1997-10-16 | 2002-03-28 | Budny John A. | Compositions for treating biofilm |
US6033705A (en) * | 1998-07-08 | 2000-03-07 | Isaacs; Charles E. | Method for treating foodstuffs to reduce or prevent microbial activity |
US6080401A (en) * | 1998-11-19 | 2000-06-27 | Reddy; Malireddy S. | Herbal and pharmaceutical drugs enhanced with probiotics |
AU764855B2 (en) * | 1998-12-15 | 2003-09-04 | Rhodia Inc. | Broad-range antibacterial composition |
JP2000270858A (en) * | 1999-03-26 | 2000-10-03 | Taiyo Kagaku Co Ltd | Lysozyme-saccharide conjugate |
US20020001582A1 (en) * | 1999-04-21 | 2002-01-03 | Charter Edward A. | Methods and compositions for inhibiting microbial growth |
US6451365B1 (en) * | 2000-07-14 | 2002-09-17 | Rhodia Inc. | Antibacterial composition for control of gram positive bacteria in food applications |
US6280725B1 (en) * | 2000-01-18 | 2001-08-28 | Lipton, Division Of Conopco, Inc. | Compositions and methods for inhibiting the growth of fungi |
US6287617B1 (en) * | 2000-02-02 | 2001-09-11 | Rhodia Inc. | Gram negative antibacterial composition |
GB2379166A (en) * | 2002-10-22 | 2003-03-05 | Dsm Nv | Animal feed |
-
2002
- 2002-09-18 CA CA002404356A patent/CA2404356A1/en not_active Abandoned
-
2003
- 2003-09-18 DK DK03797125T patent/DK1539224T3/en active
- 2003-09-18 JP JP2004536716A patent/JP4664678B2/en not_active Expired - Fee Related
- 2003-09-18 CA CA2498143A patent/CA2498143C/en not_active Expired - Fee Related
- 2003-09-18 WO PCT/CA2003/001359 patent/WO2004026334A1/en active IP Right Grant
- 2003-09-18 US US10/528,210 patent/US20050266050A1/en not_active Abandoned
- 2003-09-18 ES ES03797125T patent/ES2298614T3/en not_active Expired - Lifetime
- 2003-09-18 EP EP03797125A patent/EP1539224B1/en not_active Expired - Lifetime
- 2003-09-18 EP EP20070121562 patent/EP1902724A3/en not_active Ceased
- 2003-09-18 DE DE60317799T patent/DE60317799T2/en not_active Expired - Lifetime
- 2003-09-18 AU AU2003266058A patent/AU2003266058A1/en not_active Abandoned
- 2003-09-18 BR BRPI0314118A patent/BRPI0314118B1/en not_active IP Right Cessation
-
2010
- 2010-04-01 US US12/752,596 patent/US20110014178A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62145025A (en) * | 1985-12-18 | 1987-06-29 | Nippon Kayaku Co Ltd | Antiviral agent |
EP0466244A1 (en) * | 1990-07-13 | 1992-01-15 | Unilever N.V. | Compositions having antibacterial properties and use of such compositions in suppressing growth of microorganisms, eg. Listeria bacteria |
EP0955061A1 (en) * | 1998-03-20 | 1999-11-10 | Medipharm CZ, s.r.o. | Oral product for the prevention and therapy of porcine gastroenteric infections |
Non-Patent Citations (1)
Title |
---|
PATENT ABSTRACTS OF JAPAN vol. 011, no. 371 (C - 462) 3 December 1987 (1987-12-03) * |
Cited By (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8691773B2 (en) | 2006-04-06 | 2014-04-08 | Sanofi-Aventis Spa | Peptide compound with biological activity, its preparation and its applications |
EA015943B1 (en) * | 2006-04-06 | 2011-12-30 | Санофи-Авентис Спа | Peptide compound with antimicrobial activity, obtained from bacillus clausii, and application thereof |
AU2007232210B2 (en) * | 2006-04-06 | 2012-11-15 | Sanofi-Aventis Spa | Peptide compound with biological activity, its preparation and its application |
WO2007113691A3 (en) * | 2006-04-06 | 2007-12-27 | Sanofi Aventis Spa | Peptide compound with biological activity, its preparation and its application |
NO341813B1 (en) * | 2006-04-06 | 2018-01-29 | Sanofi Aventis Spa | Peptide Compound with Biological Activity, Its Preparation, Pharmaceutical Compositions Containing Such and Their Uses |
EP2124575A2 (en) * | 2006-12-26 | 2009-12-02 | Sterilex Technologies, LLC | Antimicrobial compositions |
EP2124575A4 (en) * | 2006-12-26 | 2013-01-09 | Sterilex Technologies Llc | Antimicrobial compositions |
WO2011104339A1 (en) | 2010-02-25 | 2011-09-01 | Novozymes A/S | Variants of a lysozyme and polynucleotides encoding same |
WO2012035103A1 (en) | 2010-09-16 | 2012-03-22 | Novozymes A/S | Lysozymes |
US9663775B2 (en) | 2011-11-25 | 2017-05-30 | Novozymes A/S | Polypeptides having lysozyme activity and polynucleotides encoding same |
US10039300B2 (en) | 2011-11-25 | 2018-08-07 | Novozymes A/S | Polypeptides having lysozyme activity and compositions comprising it |
WO2013076259A3 (en) * | 2011-11-25 | 2013-07-25 | Novozymes A/S | Polypeptides having lysozyme activity and polynucleotides encoding same |
JP2015506667A (en) * | 2011-11-25 | 2015-03-05 | ノボザイムス アクティーゼルスカブ | Polypeptide having lysozyme activity and polynucleotide encoding the same |
US10829750B2 (en) | 2011-11-25 | 2020-11-10 | Novozymes A/S | Polypeptides having lysozyme activity and polynucleotides encoding same |
US10829751B2 (en) | 2011-11-25 | 2020-11-10 | Novozyems A/S | Polypeptides having lysozyme activity and polynucleotides encoding same |
WO2013076253A1 (en) | 2011-11-25 | 2013-05-30 | Novozymes A/S | Polypeptides having lysozyme activity and polynucleotides encoding same |
US9701952B2 (en) | 2011-11-25 | 2017-07-11 | Novozymes A/S | Polypeptides having lysozyme activity and polynucleotides encoding same |
US10119130B2 (en) | 2011-11-25 | 2018-11-06 | Novozymes A/S | Polypeptides having lysozyme activity and compositions comprising it |
WO2013076259A2 (en) | 2011-11-25 | 2013-05-30 | Novozymes A/S | Polypeptides having lysozyme activity and polynucleotides encoding same |
US9689014B2 (en) | 2012-01-23 | 2017-06-27 | Morphosys Ag | Use of lysozyme as a tag |
WO2013110627A1 (en) | 2012-01-23 | 2013-08-01 | Morphosys Ag | Use of lysozyme as a tag |
US10568344B2 (en) | 2015-07-02 | 2020-02-25 | Novozymes A/S | Methods of improving animal performance |
EP4032409A1 (en) | 2015-07-02 | 2022-07-27 | Novozymes A/S | Animal feed comprising a feed additive for improving animal performance |
WO2017001703A1 (en) | 2015-07-02 | 2017-01-05 | Novozymes A/S | Methods of improving animal performance |
WO2017140807A1 (en) | 2016-02-16 | 2017-08-24 | Monaghan Mushrooms Group | Fungal polypeptides having lysozyme activity |
US11685911B2 (en) | 2016-02-16 | 2023-06-27 | Monaghan Mushroom S Group | Fungal polypeptides having lysozyme activity |
WO2018127532A1 (en) | 2017-01-04 | 2018-07-12 | Novozymes A/S | Microbial lysozyme for use in the treatment of irritable bowel syndrome or inflammatory bowel disease |
EP4052722A1 (en) | 2017-01-04 | 2022-09-07 | Novozymes A/S | Compositions for human treatment |
US11179447B2 (en) | 2017-01-04 | 2021-11-23 | Novozymes A/S | Microbial lysozyme for use in the treatment of irritable bowel syndrome or inflammatory bowel disease |
US11859170B2 (en) | 2017-05-12 | 2024-01-02 | Novozymes A/S | Polypeptides having lysozyme activity, polynucleotides encoding same and uses and compositions thereof |
WO2019043191A1 (en) | 2017-09-01 | 2019-03-07 | Novozymes A/S | Animal feed additives comprising a polypeptide having protease activity and uses thereof |
WO2019043189A1 (en) | 2017-09-01 | 2019-03-07 | Novozymes A/S | Animal feed additives comprising polypeptide having protease activity and uses thereof |
WO2019170682A1 (en) | 2018-03-05 | 2019-09-12 | Novozymes A/S | Ruminant feed composition comprising a muramidase |
US11857596B2 (en) | 2018-03-16 | 2024-01-02 | Ajinomoto Co., Inc. | Animal feed additive and animal feed |
WO2019177171A1 (en) | 2018-03-16 | 2019-09-19 | 味の素株式会社 | Animal feed additive and animal feed |
WO2020043836A1 (en) | 2018-08-31 | 2020-03-05 | Novozymes A/S | Polypeptides having protease activity and polynucleotides encoding same |
WO2020053275A3 (en) * | 2018-09-11 | 2020-04-30 | Dsm Ip Assets B.V. | Animal feed composition comprising muramidase and use thereof |
WO2020053271A1 (en) | 2018-09-11 | 2020-03-19 | Dsm Ip Assets B.V. | Animal feed composition and use thereof |
WO2020053274A1 (en) | 2018-09-11 | 2020-03-19 | Dsm Ip Assets B.V. | Animal feed composition and use thereof |
WO2020053275A2 (en) | 2018-09-11 | 2020-03-19 | Dsm Ip Assets B.V. | Animal feed composition and use thereof |
WO2020053273A1 (en) | 2018-09-11 | 2020-03-19 | Dsm Ip Assets B.V. | Animal feed composition and use thereof |
WO2020053276A1 (en) | 2018-09-11 | 2020-03-19 | Dsm Ip Assets B.V. | Animal feed composition and use thereof |
JP7484885B2 (en) | 2018-09-11 | 2024-05-16 | ディーエスエム アイピー アセッツ ビー.ブイ. | Animal feed composition and use thereof |
WO2020058223A1 (en) | 2018-09-17 | 2020-03-26 | Dsm Ip Assets B.V. | Animal feed composition and use thereof |
WO2020182602A1 (en) | 2019-03-11 | 2020-09-17 | Novozymes A/S | Fibrous maize-based animal feed with gh30 glucuronoxylan hydrolase |
WO2022194728A1 (en) | 2021-03-16 | 2022-09-22 | Dsm Ip Assets B.V. | Animal feed composition and use thereof |
Also Published As
Publication number | Publication date |
---|---|
US20050266050A1 (en) | 2005-12-01 |
EP1539224A1 (en) | 2005-06-15 |
ES2298614T3 (en) | 2008-05-16 |
DE60317799T2 (en) | 2008-11-20 |
BRPI0314118B1 (en) | 2016-05-10 |
DK1539224T3 (en) | 2008-03-31 |
JP4664678B2 (en) | 2011-04-06 |
EP1902724A3 (en) | 2008-07-02 |
CA2498143C (en) | 2012-11-06 |
JP2005539070A (en) | 2005-12-22 |
EP1902724A2 (en) | 2008-03-26 |
BR0314118A (en) | 2005-07-12 |
US20110014178A1 (en) | 2011-01-20 |
EP1539224B1 (en) | 2007-11-28 |
AU2003266058A1 (en) | 2004-04-08 |
CA2498143A1 (en) | 2004-04-01 |
DE60317799D1 (en) | 2008-01-10 |
CA2404356A1 (en) | 2004-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2498143C (en) | Antimicrobial composition and method for use | |
Hajati | Application of organic acids in poultry nutrition | |
US20060134091A1 (en) | Additive for an animal feed | |
US20060083731A1 (en) | Use of an enzyme for the manufacture of an agent for controlling bacterial infection | |
Wang et al. | Effects of flavomycin, Bacillus licheniformis and enramycin on performance, nutrient digestibility, gut morphology and the intestinal microflora of broilers | |
EP0681787B1 (en) | Use of an enzyme for manufacturing an agent for the treatment and/or prophylaxis of coccidiosis | |
Youssef et al. | Influence of dietary chitosan-oligosaccharides supplementation on productive and reproductive performance of laying hens | |
EP3592154A1 (en) | Feed additive formulation and methods of making and using the same | |
JP2022500358A (en) | Animal feed composition and its use | |
Вели | All-Russian Research Veterinary Institute of Pathology, Pharmacology and Therapy BACTERIOCIN PRODUCTION AS A MECHANISM FOR THE ANTI-INFECTIVE ACTIVITY OF LACTOBACILLUS SALIVARIUS UCC118 | |
Botlhoko | Performance of Clostridium perfringens-challenged broilers inoculated with Effective Microorganisms | |
Schmidt | Application of egg by-products as high quality protein, energy and bactericidal supplements in poultry and swine nutrition | |
Awati | How xylanase can enhance swine productivity | |
Caballero | Diarrhoea? Egg powder to the rescue | |
Patil | From basketball to feed milling: a common tactic for winning in 2023 | |
Ilic | Secondary plant compounds are the new frontier in poultry nutrition | |
Diaconu | Antioxidants–Helping pigs to cope with oxidative stress |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2498143 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003797125 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10528210 Country of ref document: US Ref document number: 2004536716 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003797125 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003797125 Country of ref document: EP |